{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:34:24Z","timestamp":1790213664871,"version":"4.1.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Posaconazole is a triazole antifungal with activity against <jats:italic toggle=\"yes\">Rhizopus<\/jats:italic>, but data on its use and pharmacokinetics in preterm infants are scarce. In this case, a 24 4\/7-week neonate\u2019s <jats:italic toggle=\"yes\">Rhizopus<\/jats:italic> infection is successfully treated with debridement and combination antifungal therapy with amphotericin B, micafungin and enteral posaconazole. This is the first reported posaconazole use in a preterm neonate with <jats:italic toggle=\"yes\">Rhizopus<\/jats:italic>.<\/jats:p>","DOI":"10.1097\/inf.0000000000002554","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T19:25:47Z","timestamp":1582313147000},"page":"310-312","source":"Crossref","is-referenced-by-count":9,"title":["Rhizopus Infection in a Preterm Infant: A Novel Use of Posaconazole"],"prefix":"10.1097","volume":"39","author":[{"given":"Roxana","family":"Fatemizadeh","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rodman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, Texas"},{"name":"Department of Pharmacy, Texas Children\u2019s Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Demmler-Harrison","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Dinu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 5","key":"R1-20230912","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1469-0691.2009.02981.x","article-title":"Invasive zygomycosis in neonates and children.","volume":"15","author":"Roilides","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R3-20230912","article-title":"Primary cutaneous aspergillosis in a preterm neonate: potential therapeutic role of posaconazole.","author":"Subudhi","year":"2008","journal-title":"Intersci Conf Antimicrob Agents Chemother"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1128\/AAC.04424-14","article-title":"Susceptibility profiles of amphotericin B and posaconazole against clinically relevant mucorales species under hypoxic conditions.","volume":"59","author":"Maurer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11908-016-0520-2","article-title":"Pyomyositis in children.","volume":"18","author":"AJ","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40262-018-0658-1","article-title":"Clinical pharmacokinetics and dose recommendations for posaconazole in infants and children.","volume":"58","author":"Boonsathorn","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.00868-08","article-title":"Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.","volume":"53","author":"S\u00e1ez-Llorens","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/11319340-000000000-00000","article-title":"Pharmacokinetic\/pharmacodynamic profile of posaconazole.","volume":"49","author":"Li","year":"2010","journal-title":"Clin Pharmacokinet"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:34:22Z","timestamp":1694558062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002554","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}